PriceTargets.com logo

SQZ Biotechnologies - SQZB Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.05 As of 04/26/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for SQZB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SQZ Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SQZB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SQZB

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for SQZ Biotechnologies in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.05.

This chart shows the closing price for SQZB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 polled investment analysts is to hold stock in SQZ Biotechnologies. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/15/2023Brookline Capital ManagementDowngradeBuy ➝ Hold
(Data available from 4/28/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.

SQZ Biotechnologies

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $0.05
Low: $0.05
High: $0.05

50 Day Range

MA: $0.05
Low: $0.04
High: $0.05

52 Week Range

Now: $0.05
Low: $0.01
High: $0.69

Volume

N/A

Average Volume

30,409 shs

Market Capitalization

$1.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Frequently Asked Questions

What sell-side analysts currently cover shares of SQZ Biotechnologies?

The following Wall Street research analysts have issued research reports on SQZ Biotechnologies in the last year: Brookline Capital Management.
View the latest analyst ratings for SQZB.

What is the current price target for SQZ Biotechnologies?

0 Wall Street analysts have set twelve-month price targets for SQZ Biotechnologies in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for SQZ Biotechnologies in the next year.
View the latest price targets for SQZB.

What is the current consensus analyst rating for SQZ Biotechnologies?

SQZ Biotechnologies currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SQZB, but not buy more shares or sell existing shares.
View the latest ratings for SQZB.

What other companies compete with SQZ Biotechnologies?

Other companies that are similar to SQZ Biotechnologies include SQZ Biotechnologies, Windtree Therapeutics, TC Biopharm, Scinai Immunotherapeutics and Acorda Therapeutics. Learn More about companies similar to SQZ Biotechnologies.

How do I contact SQZ Biotechnologies' investor relations team?

SQZ Biotechnologies' physical mailing address is 200 Arsenal Yards Boulevard, Suite 210, Watertown, MA 02472, United States. The company's listed phone number is 617-758-8672 and its investor relations email address is [email protected]. The official website for SQZ Biotechnologies is www.sqzbiotech.com. Learn More about contacing SQZ Biotechnologies investor relations.